(1) Adult aged >=18 years and agrees to sign the informed consent, (2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR, (3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in the lungs, which were obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, the changes may not be present in mild patients, (4) Hospitalized patients with fever (axillary temperature >=37.0 degree C) or respiratory symptoms, (5) The interval between symptom onset and randomization was within 12 days, (6) Did not participate in other clinical researches within 3 months, (7) Do not participate other antiviral studies within 28 days of follow-up.

(1) Adult aged >=18 years and agrees to sign the informed consent, (2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR, (3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in the lungs, which were obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, the changes may not be present in mild patients, (4) Hospitalized patients with fever (axillary temperature >=37.0 degree C) or respiratory symptoms, (5) The interval between symptom onset and randomization was within 12 days, (6) Did not participate in other clinical researches within 3 months, (7) Do not participate other antiviral studies within 28 days of follow-up.